Kezar Life Sciences KZR 深 滬
已收盤 05-11 16:00:00 美东时间
7.29
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 7.29
- 總市值 5385.63万
- 52周最高 7.55
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.5334
- 委 比 0.00%
- 總股本 738.77万
- 歷史最高 363.27
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.5334
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tang Capital takes 10% stake in Aurinia Pharma
Tang Capital Management Tuesday said that it acquired 206,005 common shares of Aurinia Pharmaceuticals (AUPH) at a price of $15.28 per share for an aggregate purchase price of $3.1M. As a result of th...
06-03 15:54
Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq
An update from Kezar Life Sciences ( ($KZR) ) is now available. On May 11, 2026...
05-11 22:03
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. On May 8, 2026, Au...
05-11 21:59
Kezar Life Sciences Announces Major Executive Leadership Changes
Kezar Life Sciences ( ($KZR) ) has issued an announcement. On April 1, 2026, Ke...
04-04 05:27
Aurinia Pharmaceuticals acquiring Kezar Life Sciences
Aurinia Pharmaceuticals (AUPH) is acquiring Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one contingent value right. The CVR gives the shareholder the right to re...
03-30 22:06
Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
03-30 20:04
Enodia Therapeutics Acquires Kezar Life Sciences Preclinical Assets For Up to $127M Plus Royalties
Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory
03-12 21:06
Kezar Life Sciences Q3 EPS $(1.53) Beats $(2.08) Estimate
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.08) by 26.3 percent. This is a 44.96 percent increase over losses of $(2.78) per share from
2025-11-13 05:33
Kezar Life Sciences Announces Two Presentations From Completed Phase 2a PORTOLA Clinical Trial In Patients With Autoimmune Hepatitis At 2025 AASLD
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the
2025-11-07 20:08
